| Literature DB >> 14638774 |
Andrea E Hall1, Paul J Domanski, Pratiksha R Patel, John H Vernachio, Peter J Syribeys, Elena L Gorovits, Michael A Johnson, Julia M Ross, Jeff T Hutchins, Joseph M Patti.
Abstract
The Staphylococcus aureus MSCRAMM (microbial surface components recognizing adhesive matrix molecules) protein clumping factor A (ClfA) has been shown to be a critical virulence factor in several experimental models of infection. This report describes the generation, characterization, and in vivo evaluation of a murine monoclonal antibody (MAb) against ClfA. Flow cytometric analysis revealed that MAb 12-9 recognized ClfA protein expressed by all of the clinical S. aureus strains obtained from a variety of sources. In assays measuring whole-cell S. aureus binding to human fibrinogen, MAb 12-9 inhibited S. aureus binding by over 90% and displaced up to 35% of the previously adherent S. aureus bacteria. Furthermore, a single infusion of MAb 12-9 was protective against an intravenous challenge with a methicillin-resistant strain of S. aureus in a murine sepsis model (P < 0.0001). These data suggest that anti-ClfA MAb 12-9 should be further investigated as a novel immunotherapy for the treatment and prevention of life-threatening S. aureus infections.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14638774 PMCID: PMC308922 DOI: 10.1128/IAI.71.12.6864-6870.2003
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441